In some test subjects, the drug, CNP520 or umibecestat, appears to lead to worsening of cognitive function or loss of memory. The researchers then concluded that the potential benefit of the drug outweighs the risk. CNP520 had to slow or even prevent the development of Alzheimer's disease in people at high risk.
A spokesman for Novartis says he is disappointed, but stresses that anti-Alzheimer's research and other neurological illnesses continue.
Alzheimer's disease is the most common form of dementia. Whoever is getting more and more memory problems.
The most important news in your mailbox every day at noon?
Invalid email address. Please re-enter.
You can unsubscribe with 1 click